Items where authors include "Burger, JA"

Article

Solman, IG, Blum, LK, Hoh, HY et al. (11 more authors) (2020) Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia. Leukemia Research. 106432. p. 106432. ISSN 0145-2126

Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609

O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609

Barrientos, JC, Burger, JA, Byrd, JC et al. (5 more authors) (2019) Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia & Lymphoma, 60 (4). pp. 1000-1005. ISSN 1042-8194

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924

Brown, JR, Moslehi, J, O' Brien, S et al. (24 more authors) (2017) Characterization Of Atrial Fibrillation Adverse Events Reported In Ibrutinib Randomized Controlled Registration Trials. Haematologica, 102 (10). pp. 1796-1805. ISSN 0390-6078

Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971

Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793